CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes
Event

Investors

OMX Stockholm

( %)
HNSA  SEK

Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.

Antibodies
Latest Financial Results

Interim report January-June 2025

View all results
Calendar

Upcoming events

16
Sep

Pareto Securities’ 16th Annual Healthcare Conference 2025

23
Oct

Interim Report for January-September 2025

13
Nov

SEB Healthcare Conference, Stockholm

View all events

Press releases

Our latest press releases

Hansa Biopharma in brief

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.

Page: /

Hansa Biopharma Corporate Presentation April 2025

View presentation

Annual Report 2024
Sustainability Report 2024

Science-led
Patient first
Values driven

Read the reports

Key progress and look ahead

Desensitization: Transplantation and Gene Therapy

Phase 3 Top Line Data Readout: pivotal US trial in kidney transplantation (ConfIdeS)

Phase 1b Initial Data Readout: global trial in Duchenne Muscular Dystrophy with Sarepta (SRP-9001-104)

Phase 2 Top Line Data Readout: global trial in Crigler Najjar with Genethon (GNT-018-IDES)

Autoimmune Disease

Phase 3 Top Line Data Readout: global trial in anti-GBM (GOOD-IDES-02)

Phase 2 Data Publication: single arm trial in GBS (15-HMedIdeS-09)

Investor relations

Evan Ballantyne

Chief Financial Officer

Email: [email protected]

E-mail

Sign up to receive the latest updates

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.